Nuvectis Pharma Q3 2026 Results: Net Loss of $30.1M, Loss Widens
Nuvectis Pharma reported a significant increase in cash and cash equivalents to $140.7 million as of September 30, 2026, following a substantial equity issuance. However, the company continues to incur losses, with research and development expenses rising to $36.2 million for the first nine months of 2026 compared to $13.1 million in the prior year period.
- Key figure
- Net loss $30.1M